Literature DB >> 26981948

Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia.

Ranjit Nair1, Shereen Gheith1, Suresh G Nair1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26981948     DOI： 10.1056/NEJMc1509362

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  21 in total

1.  Supportive care for patients undergoing immunotherapy.

Authors:  Bernardo Leon Rapoport; Ronwyn van Eeden; Vincent Sibaud; Joel B Epstein; Jean Klastersky; Matti Aapro; Devan Moodley
Journal:  Support Care Cancer       Date:  2017-07-13       Impact factor: 3.603

2.  Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia.

Authors:  Jad Othman; Emma Verner; Constantine S Tam; Jane Huang; Leo Lin; James Hilger; Judith Trotman; Robin Gasiorowski
Journal:  Haematologica       Date:  2018-02-08       Impact factor: 9.941

3.  Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin.

Authors:  Sandra D Algaze; Wungki Park; Thomas J Harrington; Raja Mudad
Journal:  BMJ Case Rep       Date:  2018-03-09

4.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

5.  Pembrolizumab-Induced Pancytopenia: A Case Report.

Authors:  Dinesh Atwal; Krishna P Joshi; Rahul Ravilla; Fade Mahmoud
Journal:  Perm J       Date:  2017

6.  Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.

Authors:  Rebecca Karp Leaf; Christopher Ferreri; Deepa Rangachari; James Mier; Wesley Witteles; George Ansstas; Theodora Anagnostou; Leyre Zubiri; Zofia Piotrowska; Thein H Oo; David Iberri; Mark Yarchoan; April K S Salama; Douglas B Johnson; Andrew D Leavitt; Osama E Rahma; Kerry L Reynolds; David E Leaf
Journal:  Am J Hematol       Date:  2019-03-13       Impact factor: 13.265

7.  Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.

Authors:  Xuexiang Du; Mingyue Liu; Juanjuan Su; Peng Zhang; Fei Tang; Peiying Ye; Martin Devenport; Xu Wang; Yan Zhang; Yang Liu; Pan Zheng
Journal:  Cell Res       Date:  2018-02-20       Impact factor: 25.617

Review 8.  Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.

Authors:  Marianne Davies; Emily A Duffield
Journal:  Immunotargets Ther       Date:  2017-08-24

9.  Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.

Authors:  Andrew Hantel; Brooke Gabster; Jason X Cheng; Harvey Golomb; Thomas F Gajewski
Journal:  J Immunother Cancer       Date:  2018-07-16       Impact factor: 13.751

10.  Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer.

Authors:  Yuriko Ueki; Manabu Suzuki; Yuriko Horikawa; Hiromu Watanabe; Yoh Yamaguchi; Chie Morita; Akinari Tsukada; Hiroshi Takumida; Yusaku Kusaba; Takashi Katsuno; Yoshie Tsujimoto; Keita Sakamoto; Masao Hashimoto; Junko Terada; Satoru Ishii; Jin Takasaki; Go Naka; Motoyasu Iikura; Shinyu Izumi; Yuichiro Takeda; Masayuki Hojo; Haruhito Sugiyama
Journal:  Thorac Cancer       Date:  2020-08-07       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.